Boehringer Ingelheim Chooses IDBS’ PredictionBase

IDBS, a provider of drug discovery data management solutions, today announced that the global pharmaceutical company Boehringer Ingelheim (Ingelheim, Germany) has purchased IDBS’ predictive modelling technology PredictionBase for use at its Biberach an der Riss research site.

Scientists at the Biberach facility, where research into diseases of the central nervous system (CNS), metabolic diseases and respiratory diseases is centred, will use PredictionBase to build and deploy and distribute predictive ADME QSAR models using existing data.

Boehringer Ingelheim sought a solution that would help reduce the effort required for scientists to perform prediction manually, while also efficiently distributing valuable drug discovery knowledge throughout the company. PredictionBase provided the required predictive technology to integrate with existing Boehringer Ingelheim IT tools to form an automated workflow, allowing scientists to save time by prioritizing work, so improving efficiency.

Neil Kipling, founder and CEO of IDBS, commented: "Increasingly, organizations are opting for predictive technologies that help reduce costs incurred by failed candidates by weeding out potential failures before screening begins. Boehringer Ingelheim sought to increase efficiency of the candidate identification process by introducing an automated workflow. Use of PredictionBase has helped its scientists streamline working practises when dealing with larger volumes of data.” He added: “By providing scientists with a tool to create, analyze and validate predictive models, PredictionBase enables the easy generation and distribution of knowledge across organizations.”